JP2017071603A5

JP2017071603A5 -

Info

Publication number: JP2017071603A5
Application number: JP2016198584A
Authority: JP
Filing date: 2016-10-07
Publication date: 2019-11-14

Claims

Formula (I):

(Where
X is —S— or —O—;
(I) when X is -S-
R ^3a is alkyl, haloalkyl, hydroxyalkyl or alkyloxyalkyl;
R ^2a is halogen, alkyloxy or haloalkyloxy, and when R ^3a is haloalkyl, R ^2a may be alkyl;
R ^2b is H;
R ^2a and R ^2b together with the carbon atom to which they are attached may form a substituted cycloalkane;
When R ^2a and R ^2b together with the carbon atom to which they are attached form a substituted cycloalkane, R ^3a may be H;

(Ii) when X is -O-
R ^3a is haloalkyl optionally substituted with one or more groups selected from alkyloxy and cycloalkyl, or cycloalkyl substituted with one or more groups selected from halogen;
R ^2a is H, halogen, alkyl, alkyloxy or haloalkyloxy,
R ^2b is H;
R ^2a and R ^2b together with the carbon atom to which they are attached may form a substituted cycloalkane;
When R ^2a and R ^2b together with the carbon atom to which they are attached form a substituted cycloalkane, R ^3a may be H or alkyl;

R ^3b is H or alkyl;

May be,
Ring A is a substituted or unsubstituted aromatic carbocyclic ring, a substituted or unsubstituted nonaromatic carbocyclic ring, a substituted or unsubstituted aromatic heterocyclic ring or a substituted or unsubstituted nonaromatic heterocyclic ring,
Ring B is a substituted or unsubstituted aromatic carbocyclic ring, a substituted or unsubstituted non-aromatic carbocyclic ring, a substituted or unsubstituted aromatic heterocyclic ring or a substituted or unsubstituted non-aromatic heterocyclic ring,
R ¹ is substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl or substituted or unsubstituted cycloalkyl;
R ⁵ is halogen or substituted or unsubstituted alkyl;
n is an integer from 0 to 2,
However, the following compounds are excluded.
(1) a compound wherein X is —O—, R ^3a is CH ₂ F or CF ₃ , R ^3b is H, R ^2a is H , and R ^2b is H,
(2) a compound wherein X is —O—, R ^3a is CHF ₂ , R ^3b is H, R ^2a is OMe and R ^2b is H, and
(3) The following compounds:

)
Or a pharmaceutically acceptable salt thereof .

The compound according to claim 1, wherein X is -O- in formula (I), or a pharmaceutically acceptable salt thereof.

^{R 3a} is _CH 2 _F in Formula (I), _{CHF 2, CF 3, CH (} F) CH 3 or _CF 2 CH ^{_3, R 3b} is Ri H or CH ₃ ^{der; R 2a} is H, F, CH ₃ , OCH ₃ or OCH ₂ CF ₃ ; R ¹ is alkyl;
Ring A is

(Wherein R ⁴ is H or halogen, -Z = is -CH = or -N =)
Is;
The compound according to claim 1 or 2, wherein ring B is substituted or unsubstituted pyridine, substituted or unsubstituted pyrazine, substituted or unsubstituted pyrimidine, substituted or unsubstituted pyridazine or substituted or unsubstituted oxazole, or a compound thereof Pharmaceutically acceptable salt.

R ^２ａ2a The compound or pharmaceutically acceptable salt thereof according to any one of claims 1 to 3, wherein is F.

A pharmaceutical composition comprising the compound according to any one of claims 1 to 4 or a pharmaceutically acceptable salt thereof.